The Experts below are selected from a list of 138 Experts worldwide ranked by ideXlab platform
K V Soares - One of the best experts on this subject based on the ideXlab platform.
-
Cholinergic medication for neuroleptic-induced tardive dyskinesia.
The Cochrane database of systematic reviews, 2000Co-Authors: J J Mcgrath, K V SoaresAbstract:Since the 1950's neuroleptic medication has been extensively used to treat people with chronic mental illnesses, such as schizophrenia. These may cause tardive dyskinesia (TD), abnormal, repetitive and involuntary movements, in up to 20% of those using the medication for longer than three months. One theory of causation supports the use of cholinergic drugs for the management of TD. To determine whether the use of cholinergic agents (arecoline, choline, Deanol, lecithin, meclofenoxate, physostigmine, RS 86) were associated with clinical improvement in neuroleptic-induced TD in people with schizophrenia or other chronic mental illnesses. Electronic searches of Biological Abstracts (1982-1995), Cochrane Schizophrenia Group's Register of trials (1995), EMBASE (1980-1995), LILACS (1982-1996), MEDLINE (1966-1995), PsycLIT (1974-1995), and SCISEARCH (1995) were undertaken. References of all identified studies were searched for further trial citations. Principal authors of trials were contacted. Reports identified in the search were included if they were controlled trials dealing with people with neuroleptic-induced TD and schizophrenia or other chronic mental illnesses who had been randomly allocated to either a cholinergic agent or to a placebo (or no intervention). Seven different studies (8 references) were included in this review, and another ten trials are currently awaiting further data from authors. Data were independently extracted from these trials by each reviewer and odds ratios (OR) or average differences, with the 95% confidence intervals (95% CI) were estimated. The reviewers assumed that people who dropped out had no improvement. The studies failed to detect any significant advantage of Deanol or lecithin when compared to placebo. Data from two Deanol trials demonstrated an excess of side effects in the active treatment group. People on cholinergic compounds report a range of gastrointestinal adverse effects (anorexia, nausea, vomiting, diarrhea, abdominal pain), sedation, and undesirable body odour. One person died of acute aspiration in a Deanol versus placebo cross-over study. This review provides no strong evidence for the use of cholinergic agents in the treatment of neuroleptic-induced tardive dyskinesia. While people receiving cholinergic treatment had a marginal benefit compared to placebo, because of the small sample size, the cumulative data must be interpreted as inconclusive. Clinicians and trialists considering using cholinergic agents to treat TD should balance the lack of evidence for the efficacy against the excess of side effects associated with these compounds.
J J Mcgrath - One of the best experts on this subject based on the ideXlab platform.
-
Cholinergic medication for neuroleptic-induced tardive dyskinesia.
The Cochrane database of systematic reviews, 2000Co-Authors: J J Mcgrath, K V SoaresAbstract:Since the 1950's neuroleptic medication has been extensively used to treat people with chronic mental illnesses, such as schizophrenia. These may cause tardive dyskinesia (TD), abnormal, repetitive and involuntary movements, in up to 20% of those using the medication for longer than three months. One theory of causation supports the use of cholinergic drugs for the management of TD. To determine whether the use of cholinergic agents (arecoline, choline, Deanol, lecithin, meclofenoxate, physostigmine, RS 86) were associated with clinical improvement in neuroleptic-induced TD in people with schizophrenia or other chronic mental illnesses. Electronic searches of Biological Abstracts (1982-1995), Cochrane Schizophrenia Group's Register of trials (1995), EMBASE (1980-1995), LILACS (1982-1996), MEDLINE (1966-1995), PsycLIT (1974-1995), and SCISEARCH (1995) were undertaken. References of all identified studies were searched for further trial citations. Principal authors of trials were contacted. Reports identified in the search were included if they were controlled trials dealing with people with neuroleptic-induced TD and schizophrenia or other chronic mental illnesses who had been randomly allocated to either a cholinergic agent or to a placebo (or no intervention). Seven different studies (8 references) were included in this review, and another ten trials are currently awaiting further data from authors. Data were independently extracted from these trials by each reviewer and odds ratios (OR) or average differences, with the 95% confidence intervals (95% CI) were estimated. The reviewers assumed that people who dropped out had no improvement. The studies failed to detect any significant advantage of Deanol or lecithin when compared to placebo. Data from two Deanol trials demonstrated an excess of side effects in the active treatment group. People on cholinergic compounds report a range of gastrointestinal adverse effects (anorexia, nausea, vomiting, diarrhea, abdominal pain), sedation, and undesirable body odour. One person died of acute aspiration in a Deanol versus placebo cross-over study. This review provides no strong evidence for the use of cholinergic agents in the treatment of neuroleptic-induced tardive dyskinesia. While people receiving cholinergic treatment had a marginal benefit compared to placebo, because of the small sample size, the cumulative data must be interpreted as inconclusive. Clinicians and trialists considering using cholinergic agents to treat TD should balance the lack of evidence for the efficacy against the excess of side effects associated with these compounds.
J. P. W. F. Lakke - One of the best experts on this subject based on the ideXlab platform.
-
Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
Acta neurologica Scandinavica, 2009Co-Authors: S. F. Lindeboom, J. P. W. F. LakkeAbstract:Deanol and placebo were administered to 10 parkinsonian patients with levodopa-induced dyskinesias in a double-blind, crossover fashion. Deanol and placebo did not differ significantly in their effects on dyskinesias. The reported properties of Deanol seem to be attributable to a placebo effect. There was no correlation with the results of the physostigmine test. Despite these disappointing results Deanol remains intriguing, because in individual cases remarkable improvements on dyskinesias are reported.
M Holzgraefe - One of the best experts on this subject based on the ideXlab platform.
-
orofacial and respiratory tardive dyskinesia potential side effects of 2 dimethylaminoethanol Deanol
European Neurology, 1991Co-Authors: B A Haug, M HolzgraefeAbstract:A case of essential tremor since early adultness is presented, which has been treated successfully with the acetylcholine precursor 2-dimethylaminoethanol (Deanol) for 10 years. Development of a marke
-
Orofacial and Respiratory Tardive Dyskinesia: Potential Side Effects of 2-Dimethylaminoethanol (Deanol)?
European neurology, 1991Co-Authors: B A Haug, M HolzgraefeAbstract:A case of essential tremor since early adultness is presented, which has been treated successfully with the acetylcholine precursor 2-dimethylaminoethanol (Deanol) for 10 years. Development of a marked dyskinesia syndrome affecting predominantly orofacial and respiratory musculature has been noticed with this medication. Partial remission after discontinuation and a favorable response to anticholinergics are suggestive of an adverse drug effect.
-
orofacial and respiratory tardive dyskinesia potential side effects of 2 dimethylaminoethanol Deanol
European Neurology, 1991Co-Authors: B A Haug, M HolzgraefeAbstract:A case of essential tremor since early adultness is presented, which has been treated successfully with the acetylcholine precursor 2-dimethylaminoethanol (Deanol) for 10 years. Development of a marked dyskinesia syndrome affecting predominantly orofacial and respiratory musculature has been noticed with this medication. Partial remission after discontinuation and a favorable response to anticholinergics are suggestive of an adverse drug effect.
S. F. Lindeboom - One of the best experts on this subject based on the ideXlab platform.
-
Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
Acta neurologica Scandinavica, 2009Co-Authors: S. F. Lindeboom, J. P. W. F. LakkeAbstract:Deanol and placebo were administered to 10 parkinsonian patients with levodopa-induced dyskinesias in a double-blind, crossover fashion. Deanol and placebo did not differ significantly in their effects on dyskinesias. The reported properties of Deanol seem to be attributable to a placebo effect. There was no correlation with the results of the physostigmine test. Despite these disappointing results Deanol remains intriguing, because in individual cases remarkable improvements on dyskinesias are reported.
